MD ANDERSON CANCER CENTER and TESARO Inc. announced a collaboration to discover and develop small molecule product candidates against immuno-oncology targets, through the cancer center’s Institute for Applied Cancer Science. Under the agreement, TESARO will receive exclusive worldwide rights to develop and commercialize any small molecule product candidates that result from this collaboration. MD Anderson...
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
